CTOs on the Move

Cancer Genetic Consultants

www.tranin.com

 
Cancer Genetic Consultants is a Leawood, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tranin.com
  • 3649 W 132nd Ter
    Leawood, KS USA 66209
  • Phone: 913.271.0837

Executives

Name Title Contact Details

Similar Companies

Personalis

Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape.

Diagnostic Solutions Laboratory

We are pleased to offer clinicians the first of many advances, the GI-MAP™. The GI-MAP™ (GI-Microbial Assay Plus) stool test utilizes cutting edge, FDA-approved technology to provide a true DNA/PCR based stool analysis which provides actionable informa...

Better Therapeutics

Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.

Dewpoint Therapeutics

Dewpoint Therapeutics is leveraging a transformative shift in the understanding of cellular biology regulation to discover and advance breakthrough small-molecule therapeutics.

Ortho-McNeil Pharmaceutical

Ortho-McNeil Pharmaceutical, Inc. is a Raritan, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.